Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 97

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016', provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Progressive Multiple Sclerosis (PPMS)

- The report reviews pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Primary Progressive Multiple Sclerosis (PPMS) therapeutics and enlists all their major and minor projects

- The report assesses Primary Progressive Multiple Sclerosis (PPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Primary Progressive Multiple Sclerosis (PPMS) Overview 7
Therapeutics Development 8
Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) - Overview 8
Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics under Development by Companies 9
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Primary Progressive Multiple Sclerosis (PPMS) - Products under Development by Companies 13
Primary Progressive Multiple Sclerosis (PPMS) - Companies Involved in Therapeutics Development 14
F. Hoffmann-La Roche Ltd. 15
Genzyme Corporation 16
Glialogix, Inc. 17
Kyorin Pharmaceutical Co., Ltd. 18
MedDay SA 19
Santhera Pharmaceuticals Holding AG 20
Teva Pharmaceutical Industries Ltd. 21
Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
biotin - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
GLX-1112 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
GZ-402668 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
IB-MS - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ibudilast - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
idebenone - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
laquinimod sodium - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
masitinib - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
ocrelizumab - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecules for Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Scleros - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Stem Cell Therapy for CNS Disorders - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects 83
Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products 84
Primary Progressive Multiple Sclerosis (PPMS) - Product Development Milestones 85
Featured News & Press Releases 85
Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS 85
Jun 28, 2016: Roche's marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA 86
May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial 87
Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN 87
Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis 89
Feb 17, 2016: FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis 89
Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 90
Oct 20, 2015: Clinical trial shows first ever positive results in treating primary progressive and relapsing multiple sclerosis 92
Oct 10, 2015: More Results Released from Positive Phase III Clinical Trial of Ocrelizumab in Primary Progressive MS 93
Apr 23, 2015: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS 94
Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 94
Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97

List of Tables
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by AB Science SA, H2 2016 14
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 15
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Genzyme Corporation, H2 2016 16
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Glialogix, Inc., H2 2016 17
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 18
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by MedDay SA, H2 2016 19
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016 20
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects, H2 2016 83
Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products, H2 2016 84

List of Figures
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Top 10 Targets, H2 2016 23
Number of Products by Stage and Top 10 Targets, H2 2016 23
Number of Products by Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Routes of Administration, H2 2016 27
Number of Products by Stage and Routes of Administration, H2 2016 27
Number of Products by Molecule Types, H2 2016 29
Number of Products by Stage and Molecule Types, H2 2016 29
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • United States Tumor Marker Market Report 2017
    Published: 22-Feb-2017        Price: US 3800 Onwards        Pages: 96
    Notes: Sales, means the sales volume of Tumor Marker Revenue, means the sales value of Tumor Marker This report studies sales (consumption) of Tumor Marker in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Abbott - Siemens - Alere - Johnson - BD - Nova - ... Market Segment by States, covering - California - Texas......
  • United States Mildronate Market Report 2017
    Published: 22-Feb-2017        Price: US 3800 Onwards        Pages: 106
    Notes: Sales, means the sales volume of Mildronate Revenue, means the sales value of Mildronate This report studies sales (consumption) of Mildronate in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Psypharm - Latvian company - Jinan Chenghui-shuangda Chemical - Canadian Pharmacy - Grindex company - Slovakia - United Pharmacies - chemBli......
  • United States Argatroban Powder Market Report 2017
    Published: 22-Feb-2017        Price: US 3800 Onwards        Pages: 116
    Notes: Sales, means the sales volume of Argatroban Powder Revenue, means the sales value of Argatroban Powder This report studies sales (consumption) of Argatroban Powder in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Pfizer, Inc - SANDOZ - GlaxoSmithKline Plc - fresenius-kabi - Eagle Pharmaceuticals, Inc - Mitsubishi Tanabe Pharma - Teva Ph......
  • Global Nonalcoholic Steatohepatitis (NASH) Sales Market Report 2017
    Published: 22-Feb-2017        Price: US 4000 Onwards        Pages: 118
    Notes: Sales, means the sales volume of Nonalcoholic Steatohepatitis (NASH) Revenue, means the sales value of Nonalcoholic Steatohepatitis (NASH) This report studies sales (consumption) of Nonalcoholic Steatohepatitis (NASH) in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Boehringer Ingelheim?......
  • Global Finasteride Sales Market Report 2017
    Published: 22-Feb-2017        Price: US 4000 Onwards        Pages: 113
    Notes: Sales, means the sales volume of Finasteride Revenue, means the sales value of Finasteride This report studies sales (consumption) of Finasteride in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Merck - Actavis - Sandoz - Teva Pharmaceuticals - Cipla - RelonC......
  • China HIV Drugs Market Research Report 2017
    Published: 21-Feb-2017        Price: US 3200 Onwards        Pages: 116
    Notes: Sales, means the sales volume of HIV Drugs Revenue, means the sales value of HIV Drugs This report studies HIV Drugs in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Bristol-Myers Squibb - Gilead Sciences - GSK - Johnson - Merck - AbbVie - AstraZeneca - Boehringer Ingelheim - Cipla - Daii......
  • China Medicinal Vaseline Market Research Report 2017
    Published: 21-Feb-2017        Price: US 3200 Onwards        Pages: 118
    Notes: Sales, means the sales volume of Medicinal Vaseline Revenue, means the sales value of Medicinal Vaseline This report studies Medicinal Vaseline in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Company 1 - Company 2 - Company 3 - Company 4 - Company 5 - Company 6 - Company 7 - Company 8 - Company......
  • Europe Trazodone Market Report 2017
    Published: 21-Feb-2017        Price: US 3900 Onwards        Pages: 124
    Notes: Sales, means the sales volume of Trazodone Revenue, means the sales value of Trazodone This report studies sales (consumption) of Trazodone in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Teva - Angelini - Mylan - Fermion - The Piramal Group ......
  • Europe Tranylcypromine Market Report 2017
    Published: 21-Feb-2017        Price: US 3900 Onwards        Pages: 127
    Notes: Sales, means the sales volume of Tranylcypromine Revenue, means the sales value of Tranylcypromine This report studies sales (consumption) of Tranylcypromine in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Pfizer - Teva - Emcure - Novartis - Mylan -......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs